Searching News Database: Symphony
HSMN NewsFeed - 17 Jul 2018
Qfix Releases New Product to Improve Brachytherapy Workflows and Patient Transport
Qfix Releases New Product to Improve Brachytherapy Workflows and Patient Transport
HSMN NewsFeed - 24 Feb 2017
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
HSMN NewsFeed - 23 Dec 2014
Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer
Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer
HSMN NewsFeed - 8 Sep 2014
Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors
Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors
HSMN NewsFeed - 17 Feb 2014
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Published Study Validates Agendia’s MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
HSMN NewsFeed - 26 Nov 2013
Echo Therapeutics Announces Positive CE Mark Regulatory Trial Results of Symphony(R) CGM System
Echo Therapeutics Announces Positive CE Mark Regulatory Trial Results of Symphony(R) CGM System
HSMN NewsFeed - 5 Jun 2013
Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony(R) CGM System
Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony(R) CGM System
HSMN NewsFeed - 19 Nov 2012
Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
HSMN NewsFeed - 9 Aug 2012
Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
HSMN NewsFeed - 9 Jul 2012
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
HSMN NewsFeed - 1 Jun 2012
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
HSMN NewsFeed - 17 Apr 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
HSMN NewsFeed - 6 Dec 2011
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded Tissue
Agendia Introduces the SYMPHONY(TM) Breast Cancer Profile With Paraffin Embedded Tissue
HSMN NewsFeed - 30 Mar 2010
Cadence Pharmaceuticals Appoints Michael L. Eagle to its Board of Directors
Cadence Pharmaceuticals Appoints Michael L. Eagle to its Board of Directors
HSMN NewsFeed - 14 Apr 2009
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
HSMN NewsFeed - 29 Jan 2009
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
HSMN NewsFeed - 2 Dec 2008
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
HSMN NewsFeed - 3 Jun 2008
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
HSMN NewsFeed - 17 Apr 2008
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
HSMN NewsFeed - 17 Mar 2008
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
HSMN NewsFeed - 20 Nov 2007
A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
HSMN NewsFeed - 19 Sep 2007
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
HSMN NewsFeed - 9 Aug 2007
Sorin Group: ELA Medical, Inc. Enrolls First Patient in the NATURE Observational Study in the U.S.
Sorin Group: ELA Medical, Inc. Enrolls First Patient in the NATURE Observational Study in the U.S.
HSMN NewsFeed - 11 Jul 2007
Ventana's Board Unanimously Rejects Roche's Unsolicited Tender Offer as Inadequate
Ventana's Board Unanimously Rejects Roche's Unsolicited Tender Offer as Inadequate
HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
HSMN NewsFeed - 27 Mar 2007
Sapphire Therapeutics, Inc. Promotes William Polvino to CEO, Herb Conrad Elected Chairman of the Board
Sapphire Therapeutics, Inc. Promotes William Polvino to CEO, Herb Conrad Elected Chairman of the Board
HSMN NewsFeed - 23 Feb 2007
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
HSMN NewsFeed - 20 Dec 2006
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
HSMN NewsFeed - 28 Nov 2006
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
HSMN NewsFeed - 4 Oct 2006
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
HSMN NewsFeed - 8 Sep 2006
BioGenex Names Medical Technology Executive Raymond W. Cohen to Board of Directors
BioGenex Names Medical Technology Executive Raymond W. Cohen to Board of Directors
HSMN NewsFeed - 6 Sep 2006
Dynavax Establishes Collaboration for TLR-9 Agonists for Asthma and COPD With AstraZeneca
Dynavax Establishes Collaboration for TLR-9 Agonists for Asthma and COPD With AstraZeneca
HSMN NewsFeed - 10 May 2006
Siemens Showcases syngo BLADE, Next Generation of Patient Care Applications at ISMRM
Siemens Showcases syngo BLADE, Next Generation of Patient Care Applications at ISMRM
Additional items found! 23
Members Archive contains
23 additional stories matching:
Symphony
(Password required)
Symphony
(Password required)
